Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurogene Inc. - Common Stock (NQ:NGNE)

26.75 +0.09 (+0.34%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 321,078
Open 26.34
Bid (Size) 23.00 (200)
Ask (Size) 26.22 (100)
Prev. Close 26.66
Today's Range 23.93 - 26.97
52wk Range 6.875 - 74.49
Shares Outstanding 42,425,071
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Neurogene Announces First Participant Dosed in Embolden™ Registrational Trial of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire

Performance

YTD
+16.9%
+16.9%
1 Month
+3.6%
+3.6%
3 Month
+26.1%
+26.1%
6 Month
+81.6%
+81.6%
1 Year
-61.5%
-61.5%

More News

Read More
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Neurogene Announces Positive Regulatory Update for NGN-401 Gene Therapy in Rett Syndrome with Plans to Initiate Dosing in Embolden™ Registrational Trial in Q4 2025
From Neurogene Inc.
Via Business Wire
Neurogene to Participate in H.C. Wainwright Genetic Medicines Virtual Conference
From Neurogene Inc.
Via Business Wire
4 Biotech Stocks Seeing Explosive Momentum Gains
Via Benzinga
Topics ETFs Stocks
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
Via Benzinga
Neurogene Reports Second Quarter 2025 Financial Results and Highlights Recent Updates
From Neurogene Inc.
Via Business Wire
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction
Via Benzinga
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
Which stocks are moving on Tuesday?
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Which stocks are experiencing notable movement on Tuesday?
Via Chartmill
Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome
From Neurogene Inc.
Via Business Wire
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Neurogene Inc.
Via Business Wire
This Foot Locker Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Friday
Via Benzinga
Neurogene Announces Evidence-Based Monitoring and Treatment Intended to Reverse Rare Hyperinflammatory Syndrome Associated with High-Dose AAV
From Neurogene Inc.
Via Business Wire
Coinbase To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Wednesday
Via Benzinga
Stanley Black & Decker To Rally Around 24%? Here Are 10 Top Analyst Forecasts For Tuesday
Via Benzinga

Frequently Asked Questions

Is Neurogene Inc. - Common Stock publicly traded?
Yes, Neurogene Inc. - Common Stock is publicly traded.
What exchange does Neurogene Inc. - Common Stock trade on?
Neurogene Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurogene Inc. - Common Stock?
The ticker symbol for Neurogene Inc. - Common Stock is NGNE on the Nasdaq Stock Market
What is the current price of Neurogene Inc. - Common Stock?
The current price of Neurogene Inc. - Common Stock is 26.75
When was Neurogene Inc. - Common Stock last traded?
The last trade of Neurogene Inc. - Common Stock was at 11/07/25 04:00 PM ET
What is the market capitalization of Neurogene Inc. - Common Stock?
The market capitalization of Neurogene Inc. - Common Stock is 1.13B
How many shares of Neurogene Inc. - Common Stock are outstanding?
Neurogene Inc. - Common Stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.